Certolizumab-induced guttate psoriasiform dermatitis

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Certolizumab is a tumor necrosis factor (TNF) inhibitor widely used for chronic inflammatory diseases.
• TNF inhibitors are crucial in managing conditions like rheumatoid arthritis and Crohn's disease.
• Adverse dermatological reactions to TNF inhibitors, though uncommon, require careful monitoring.

Observation:

• A patient treated with certolizumab developed a distinct skin manifestation.
• The observed eruption was characterized as guttate psoriasiform.
• This represents a novel adverse effect associated with certolizumab therapy.

Findings:

• The patient's condition was identified as a drug-induced guttate psoriasiform eruption.
• Analysis suggests a potential link between certolizumab and the development of this specific rash.
• A review of the underlying mechanisms of drug-induced psoriasiform eruptions is provided.

Implications:

• This case highlights the importance of recognizing rare adverse drug reactions to TNF inhibitors.
• Understanding the mechanism of psoriasiform drug eruptions can guide clinical management.
• Further research may be needed to elucidate the specific pathways involved in certolizumab-induced psoriasis.